Showing 48 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Long-acting HIV-prevention drugs may be key to beating the epidemic in the U.S.

Editor's pick
NBC News
29 July 2021
Injectable & long-acting PrEP

Modelling suggests injectable cabotegravir is far more effective than daily oral PrEP for women

News
22 July 2021
Injectable & long-acting PrEP

IAS: Merck's long-acting HIV med hits protective levels in phase 2

Editor's pick
FierceBiotech
21 July 2021
Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

News
19 July 2021
Resistance

Injectable HIV therapy should only be given after a check for innate resistance, French study suggests

News
8 June 2021
PrEP policies & guidelines

CDC releases draft update for HIV PrEP guidance

Editor's pick
Healio
1 June 2021
Injectable & long-acting PrEP

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Editor's pick
ViiV Healthcare press release
4 May 2021
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and prevention from CROI 2021

News
23 March 2021
Injectable & long-acting HIV treatment

Injectable HIV medications must be practical and affordable, conference hears

News
15 March 2021
Finance & funding

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

News
15 March 2021
PrEP science

HPTN 083: Injectable PrEP can make breakthrough infections hard to detect

News
10 March 2021
Injectable & long-acting PrEP

Reformulated islatravir implant should provide PrEP for over a year

News
9 March 2021
Vaginal rings & topical PrEP

Products to prevent both pregnancy and HIV begin to emerge

News
2 February 2021
Injectable & long-acting PrEP

Once-a-month PrEP pill easily passes its first big test

News
27 January 2021
Injectable & long-acting PrEP

A triumph for injectable PrEP, but a sobering result for oral PrEP

News
27 January 2021
Antibody-based prevention

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

News
27 January 2021
People & personal stories

Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”

News
14 January 2021
Injectable & long-acting PrEP

What do we know about injectable PrEP?

About HIV
December 2020
Injectable & long-acting PrEP

'A shot can end the stigma': African women pin hopes on anti-HIV jab

Editor's pick
Reuters
3 December 2020
Injectable & long-acting PrEP

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

Editor's pick
ViiV press release
17 November 2020
Injectable & long-acting PrEP

Merck Launches Major Trial of Monthly Islatravir PrEP Pill for Women

Editor's pick
POZ
16 November 2020
Injectable & long-acting PrEP

Study of injectable PrEP reports the best efficacy seen yet for any form of PrEP in women

News
13 November 2020
Injectable & long-acting PrEP

Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women

Editor's pick
World Health Organization
10 November 2020
Pharmaceutical industry

GlaxoSmithKline's HIV PrEP challenge looms as ViiV's long-acting drug tops Gilead's Truvada in women

Editor's pick
FiercePharma
10 November 2020